A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 21 Mar 2023 Status changed from active, no longer recruiting to completed.
- 11 Jan 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2026.
- 06 Jul 2022 Status changed from recruiting to active, no longer recruiting.